Northwestern Genomic Risk Assessment and Management Program

西北基因组风险评估和管理计划

• 批准号: 10166110
• 负责人: REX L CHISHOLM
• 金额: $ 38.4万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-17 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10166110
• 关键词: 2019-nCoV; Acute Renal Failure with Renal Papillary Necrosis; Award; Biological Assay; Blood; Blood Coagulation Disorders; COVID-19; Clinical Data; Collaborations; Development; Disease; Electronic Medical Records and Genomics Network; Enzyme-Linked Immunosorbent Assay; Exposure to; Family; Family member; Genetic study; Genomics; Genotype; Household; Immunoglobulin G; Incidence; Individual; Infection; Institution; Knowledge; Measures; Myocarditis; Parents; Participant; Patient Recruitments; Phase; Phenotype; Predisposition; Prophylactic treatment; Research Personnel; Risk Assessment; Risk Management; Serologic tests; Severities; Severity of illness; Site; Spottings; Symptoms; Testing; Vaccines; Validation; Work; base; biobank; data warehouse; genetic analysis; genetic epidemiology; high risk; pandemic disease; polygenic risk score; programs; receptor binding; recruit; transmission process

PROJECT SUMMARY Since early 2020, COVID-19 disease spread rapidly across the US and will likely be sustained or recur periodically until an effective vaccine or prophylactic treatment is developed. The pandemic will have a large impact on the conduct of the next phase of eMERGE, including recruitment of new participants as well as development, validation, and implementation of genomic risk assessments based on polygenic risk scores (PRS). The supplement presents an opportunity for Northwestern to contribute eMERGE network efforts to promote the understanding of the genetic epidemiology and individual susceptibility to COVID-19 infection, disease severity, and complications. In support of efforts proposed in the supplement application for the coordinating center, we propose to expand Aim 1 of our eMERGE 4 application with the following aim: Create, validate and implement COVID-19 ePhenotyping for manifest disease, disease severity, and specific COVID-19 complications in the Northwestern biobank. Recognizing that decisions about ePhenotype development and implementation will be made in collaboration with the coordinating center and other participating eMERGE 4 sites, in this supplement, we propose leading phenotype development of three critical COVID-19 phenotypes 1) myocarditis, 2) acute kidney injury, and 3) coagulopathy complications. Additionally, we propose to facilitate studies of the full spectrum of COVID-19 disease including those with minimal or no symptoms, which will motivate participation in eMERGE 4 among individuals who may have been at higher risk to exposure to COVID-19. To achieve this, we will expand aim 2 of our parent eMERGE 4 application with the following 2 aims: a) provide SARS-CoV-2 serological testing for IgG to all Northwestern participants recruited into eMERGE 4 in year 1 of the award and b) facilitate SARS-CoV-2 serology testing and genotyping of cohabitating family members of eMERGE 4 participants by mail.

项目摘要 自2020年初以来，Covid-19疾病在美国迅速扩散，可能会持续或复发 周期性地直到开发有效的疫苗或预防性治疗。大流行将有一个大的 对下一阶段出现的行为的影响，包括招募新参与者以及 基于多基因风险评分的基因组风险评估的开发，验证和实施 （PR）。该补充剂为西北航空提供了一个机会 促进对遗传流行病学的理解和对Covid-19感染的个人敏感性， 疾病的严重程度和并发症。支持补充申请中提出的努力 协调中心，我们建议扩大我们出现的4应用程序的目标1，以下目的：创建，创建， 验证和实施共同疾病，疾病严重程度和特定 西北生物库中的Covid-19并发症。认识到有关ephenotype的决定 开发和实施将与协调中心和其他协调中心合作进行 参与的4个站点，在此补充中，我们提出了三个关键的领先表型开发 COVID-19表型1）心肌炎，2）急性肾脏损伤和3）凝血病并发症。此外， 我们建议促进对共同199疾病的全部研究 症状，这将激发可能处于较高风险的个体中的出现4 接触Covid-19。为了实现这一目标，我们将扩展父母的目标2 以下2个目的：a）为所有西北参与者提供SARS-COV-2血清学测试 在奖项的第1年中招募到4年，b）促进SARS-COV-2血清学测试和 同居的家人的基因分型通过邮件出现了4名参与者。